53 results about "CCR5 receptor antagonist" patented technology

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5⁺CD4⁺ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4⁺ cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5⁺CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.

Provided are methods for reducing intraocular pressure in an individual having an ocular disorder causing elevated intraocular pressure, such as glaucoma. The method comprises administering to the individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising an A₃ subtype adenosine receptor (A₃AR) antagonist, including dihydropyridine, pyridine, pyridinium salt or triazoloquinazoline, and derivatives thereof expressly having A₃AR antagonist activity, including, e.g., the nucleoside-based A₃AR antagonist, MRS-3820. Further provided is a method for ensuring the delivery of a topically administered therapeutic composition for reducing intraocular pressure, wherein the method expressly requires physically opening a channel through the corneal barrier of the patient's eye by a microneedle or micropipette to permit transport of the topical composition to the anterior chamber of the eye.

The invention discloses a new application of 1 type receptor antagonist of angiotensin II in treating tumour. Angiotensin II (Ang II) is the foremost effector of rennin-angiotensin system (RAS), the 1 type receptor of the Ang II plays an important role in propagation, migration and infiltration of tumour cells as well as in tumour angiogenesis. The 1 type receptor antagonist of the Ang II can effectively inhibit propagation and migration of tumour cells of various solid tumours such as prostate cancer, pancreatic cancer, liver cancer, gastric cancer, renal cancer and the like as well as tumour angiogenesis.

This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log₁₀ to 2.5 log₁₀ at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log₁₀ at about nine days following administration of the CCR5 receptor antagonist.

The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.

This invention provides a compound which is (R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. The compound is useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

The invention provides application of a G-protein-coupled receptor antagonist in preparing a medicine for treating glutamate receptor high-expression tumor. The G-protein-coupled receptor antagonist is aripiprazole, Aptiganel or carvedilol. The technical effect of the application provided by the invention is as follows: experiments prove that the aripiprazole, Aptiganel or carvedilol in the G-protein-coupled receptor antagonist can show better anti-tumor activity than Riluzole in the glutamate receptor high-expression human tumor cells.

The invention discloses an active polypeptide with an antagonistic chemotactic factor receptor CCR5, which has an amino acid sequence in SEQ ID NO:1 or an amino acid sequence obtained by carrying out deletion, addition, insertion and substitution of one or more amino acid residues on the amino acid sequence in SEQ ID NO:1. The invention also discloses a preparation method of the polypeptide, which comprises the following steps of: searching related protein sequences in a database; carrying out multiple alignment comparative analysis to screen out a highly conservative region for combination of a vMIP-II receptor; eliminating interference of unrelated residues through analysis simulation means; determining a target peptide sequence; synthetizing the active polypeptide by a solid-phase synthesis method; and finally testing the bioactivity of the polypeptide. The polypeptide can be used as a CCR5 receptor antagonist for the development of an anti-inflammatory drug, can be used as a lead drug for treating AIDS (Acquired Immune Deficiency Syndrome) and can also be used as a medicament with the immune regulation effect or a medicament for improving the functions of an immune system of an organism.

This method provides a method for reducing HIV-I viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-I viral load- reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-I -associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-I to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-I comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-I to the subject's CCR5CD4 cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

The present invention provides a chemically modified human Growth Hormone (hGH) receptor antagonists prepared by attaching a single polyethylene glycol moiety to the N-terminus. The chemically-modified protein according to the present invention have decreased PEGylation heterogeneity and which may also have increased binding affinity.

The invention provides a 1-(3-amino propyl) piperidyl-4-carboxyl amide derivative, which is a highly active antagonist of a chemokine receptor CCR5. The compound has broad anti-HIV (Human Immunodeficiency Virus) application prospect, has therefore high commercial value, can be applied to preparing the CCR5 receptor antagonist and particularly to preparation of medicaments for treating diseases mediated by the CCR5, such as acquired immune deficiency syndrome, asthma, rheumatoid arthritis and autoimmune diseases, and has a structural general formula which is shown in the specification.

The invention relates to the use of a 5-HT₄ receptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-ⁿbutyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of about 0.2 mg to 1.0 mg of the SB 207266 or salt thereof per kg of total body weight (measured as the free base). The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0 times the daily maintainance dose, followed by administration of the SB 207266 or salt at the daily maintainance dose on subsequent days.

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.